

Table SIII. Changes in atopic dermatitis-associated parameters after 16 weeks dupilumab treatment in patients according to clinical course

Outcome	Clinical course	Coefficient	95% CI	p-value
Total EASI	Continuous type	-1.30	-1.48, -1.12	<0.001
	Recurrent type	-1.14	-1.48, -0.81	<0.001
	Adult-onset type	-1.16	-1.52, -0.80	<0.001
HN-EASI	Continuous type	-0.13	-0.15, -0.10	<0.001
	Recurrent type	-0.11	-0.15, -0.08	<0.001
	Adult-onset type	-0.12	-0.15, -0.08	<0.001
POEM	Continuous type	-0.71	-0.82, -0.60	<0.001
	Recurrent type	-0.88	-1.00, -0.75	<0.001
	Adult-onset type	-0.72	-0.96, -0.48	<0.001
I-NRS	Continuous type	-0.24	-0.30, -0.19	<0.001
	Recurrent type	-0.27	-0.33, -0.21	<0.001
	Adult-onset type	-0.33	-0.42, -0.23	<0.001

CI: confidence interval; EASI: Eczema Area and Severity Index; HN-EASI: Head and Neck Eczema Area and Severity Index; POEM: Patient-Oriented Eczema Measure; I-NRS: Itch Numerical Rating Scale.